Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2: 27-30.
Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355: 2051-2052.
Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hiltgartner MW. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr. 1991;118(part 1): 540-545.
Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850: 227-231.
Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22: 2171-2179.
Mavrogeni SI, Gotsis ED, Markussis V, et al. T2 relaxation time study of iron overload in β-thalassemia. MAGMA. 1998;6: 7-12.
Papanikolaou N, Ghiatas A, Kattamis A, Ladis C, Kritikos N, Kattamis C. Non-invasive myocardial iron assessment in thalassaemic patients: T2 relaxometry and magnetization transfer ratio measurements. Acta Radiol. 2000;41: 348-351.
Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360: 516-520.
Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89: 739-761.
Covitz W, Espeland M, Gallagher D, Hellenbrand W, Leff S, TalnerN. The heart in sickle cell anemia: the Cooperative Study of Sickle Cell Disease (CSSCD). Chest. 1995;108: 1214-1219.
Batra AS, Acherman RJ, Wong WY, et al. Cardiac abnormalities in children with sickle cell anemia. Am J Hematol. 2002;70: 306-312.
Lorenz CH. The range of normal values of cardiovascular structures in infants, children, and adolescents measured by magnetic resonance imaging. Pediatr Cardiol. 2000;21: 37-46.
Lorenz CH, Walker ES, Morgan VL, Klein SS, Graham TP Jr. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson. 1999;1: 7-21.
Salton CJ, Chuang ML, O'Donnell CJ, et al. Gender differences and normal left ventricular anatomy in an adult population free of hypertension: a cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. J Am Coll Cardiol. 2002;39: 1055-1060.
Nienhuis AW, Griffith P, Strawczynski H, et al. Evaluation of cardiac function in patients with thalassemia major. Ann N Y Acad Sci. 1980;344: 384-396.
Shah FT, Westwood MA, Evans PJ, Porter JB. Discordance in MRI Assessment in Iron Distribution and Plasma NTBI between Transfusionally Iron Loaded Adults with Sickle Cell and Thalassemia [abstract]. Blood. 2002;100: 668a.
Vichinsky EP. Current issues with blood transfusions in sickle cell disease. Semin Hematol. 2001;38(suppl 1): 14-22.
Buja LM, Roberts WC. Iron in the heart: etiology and clinical significance. Am J Med. 1971;51: 209-221.
Vigorita VJ, Hutchins GM. Cardiac conduction system in hemochromatosis: clinical and pathologic features of six patients. Am J Cardiol. 1979; 44: 418-423.
Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331: 567-573.
Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331: 574-578.
Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101: 4632-4639.
